Diabetes Drug Breakthrough: No Plaque, No Problem

Colorful pills and a rainbow ribbon on a pink background

A powerful injectable drug slashes heart attack risk by 31% in high-risk diabetics before arteries even show plaque buildup, challenging decades of wait-and-see cardiology.

Story Snapshot

Evolocumab (Repatha) cut first major cardiovascular events by 31% in 3,655 high-risk diabetes patients without atherosclerosis.
LDL cholesterol dropped to 52 mg/dL from 111 mg/dL on placebo after 48 weeks, alongside statins.
Results from VESALIUS-CV trial subgroup, published in JAMA and presented at ACC 2026.
Secondary benefits: 31% fewer heart attacks, 34% less revascularization, 33% reduced strokes.
Shifts prevention from post-event to early intervention, aligning with aggressive LDL targets under 45 mg/dL.

VESALIUS-CV Trial Delivers Breakthrough Results

Amgen’s Phase 3 VESALIUS-CV trial followed 3,655 high-risk diabetes patients for a median 4.8 years. Researchers added evolocumab to statins and ezetimibe in patients lacking significant atherosclerosis. This subgroup faced elevated risks from diabetes duration over 10 years, insulin use, or microvascular issues. Event rates fell from 7.1% on placebo to 5% with the drug, yielding a 31% relative risk reduction in first MACE.

Nicholas A. Marston, MD, MPH from Mass General Brigham, led the analysis. He presented findings at the American College of Cardiology Annual Scientific Session March 28-30, 2026. Simultaneous JAMA publication confirmed the data. Marston stated these results should reshape prevention strategies. The trial achieved LDL-C levels below 52 mg/dL, far surpassing standard statin outcomes.

PCSK9 Inhibitors Reshape Cholesterol Management

PCSK9 inhibitors like evolocumab, approved in 2015, block a protein that destroys LDL receptors. This action delivers about 60% additional LDL reduction beyond statins. The FOURIER trial in 2017 proved benefits in secondary prevention for those with established ASCVD. VESALIUS-CV extends this to primary prevention in high-risk groups without plaque.

High-risk diabetics account for 10-20% of cardiovascular events despite statins. Residual risk persists because LDL levels stay elevated around 111 mg/dL on placebo. Evolocumab pushes levels to 52 mg/dL, targeting under 45 mg/dL as ideal. Safety profiles matched placebo, with similar adverse events reported.

Stakeholders Drive Paradigm Shift

Amgen funds and markets Repatha, seeking label expansions for primary prevention. Jay Bradner, MD, Amgen’s EVP of R&D, called the evidence unequivocal for earlier treatment. Mass General Brigham provided independent analysis credibility. ACC hosted the presentation, amplifying reach to clinicians.

Guideline bodies like ACC/AHA now face pressure to update dyslipidemia recommendations. Recent guidelines already push intensive lowering. FDA regulators and payers will decide reimbursement for broader use. Researchers advocate aligning therapy with risk, not just plaque presence.

Implications Reshape Patient Care and Markets

Short-term, high-risk diabetics gain an option to avert first heart attacks and strokes. Millions worldwide stand to benefit, particularly underserved groups. Long-term, fewer events cut healthcare burdens; a single MI exceeds $20,000 in costs against Repatha’s $5,000 annual price. Economic trade-offs favor prevention when facts show clear reductions.

The PCSK9 market surges as statins face pressure. Emerging oral rivals like enlicitide offer 60% LDL cuts but lack evolocumab’s proven track record. Uniform expert views praise the data, though broader non-diabetes studies remain needed. No major contradictions appear; subgroup benefits exceed overall trial’s 25% reduction due to focused risk.